Israel Patent Allowance for GH, IGF-1 and Obesity Vaccines to Braasch Biotech
Israel Patent Office allows patent for treatment of hormone deficiencies and obesity in humans and pets.
Garretson, SD, August 01, 2015 --(PR.com)-- Braasch Biotech LLC, an emerging biopharmaceutical company pioneering a new field of anti-somatostatin vaccines, today announced a Notice of Allowance was received from the Israel Patent Office on May 27, 2015, for Braasch’s vaccines for treatment of Growth Hormone (GH), Insulin-Like Growth Factor One (IGF-1) Deficiencies and Obesity.
The Patent Allowance provides multiply claims including: treatment of GH and IGF-1 Deficiencies, and therapeutic treatment for obesity in humans and pets. The Braasch vaccine technologies utilize specific immunological responses to somatostatin, an archetype hormone present in all vertebrates, to negate its counter-regulatory effects on GH and IGF-1. By enhancing bioavailability of both GH and IGF-1, a therapeutic effect on obesity is realized. The desired response is considered “endogenesis,” meaning it is not attributable to an external factor, such as artificial hormones.
The prevalence of human obesity has risen dramatically in the past decade and is a very serious worldwide health problem. Obesity is a risk factor for high blood pressure, heart disease, stroke, gall bladder disease, breast cancer, prostate cancer, colon cancer, and type-2 diabetes. According to the WHO, currently 1 in 5 adults is overweight with at least a third of them obese. By the year 2030, at least one half of the US population will be obese, if current trending persists.
“Like human obesity, obesity in dogs and cats is at epidemic proportions. Although prevention is always the best option, once an animal reaches the obese state, owner intervention is necessary for the pet’s continued quality of life and longevity. Currently there are no commercially available therapeutic treatments for both dogs and cats,” stated Jeralyn Kay Haffer, CEO and Chairman of Braasch. “We are now pleased the Israel Patent Office also has recognized the vaccine’s novelty and commercial utility in the fight against GH/IGF-1 Deficiencies and obesity.”
Braasch’s intellectual property portfolio includes multiple patent families with issued or pending claims directed to utility of anti-somatostatin vaccine technologies, Somatovac® for multiple metabolic challenges. These applications relate to both human and veterinary use of the technologies.
About Braasch Biotech
Braasch Biotech has pioneered a novel field of therapeutic approaches utilizing Somatovac® technologies. Currently in the Product Pipeline are vaccines for livestock productivity enhancement, increased fertility, GH/IGF-1 deficiencies and obesity treatment. To date, Braasch has multiple regulatory submissions in progress on the use of vaccines in metabolic regulation. Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota.
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.
Contact Information
Jeralyn Kay Haffer
CEO and Chairman
Tel. 605-376-8752
Fax. 605-594-6256
jeralyn@braaschbiotech.com
The Patent Allowance provides multiply claims including: treatment of GH and IGF-1 Deficiencies, and therapeutic treatment for obesity in humans and pets. The Braasch vaccine technologies utilize specific immunological responses to somatostatin, an archetype hormone present in all vertebrates, to negate its counter-regulatory effects on GH and IGF-1. By enhancing bioavailability of both GH and IGF-1, a therapeutic effect on obesity is realized. The desired response is considered “endogenesis,” meaning it is not attributable to an external factor, such as artificial hormones.
The prevalence of human obesity has risen dramatically in the past decade and is a very serious worldwide health problem. Obesity is a risk factor for high blood pressure, heart disease, stroke, gall bladder disease, breast cancer, prostate cancer, colon cancer, and type-2 diabetes. According to the WHO, currently 1 in 5 adults is overweight with at least a third of them obese. By the year 2030, at least one half of the US population will be obese, if current trending persists.
“Like human obesity, obesity in dogs and cats is at epidemic proportions. Although prevention is always the best option, once an animal reaches the obese state, owner intervention is necessary for the pet’s continued quality of life and longevity. Currently there are no commercially available therapeutic treatments for both dogs and cats,” stated Jeralyn Kay Haffer, CEO and Chairman of Braasch. “We are now pleased the Israel Patent Office also has recognized the vaccine’s novelty and commercial utility in the fight against GH/IGF-1 Deficiencies and obesity.”
Braasch’s intellectual property portfolio includes multiple patent families with issued or pending claims directed to utility of anti-somatostatin vaccine technologies, Somatovac® for multiple metabolic challenges. These applications relate to both human and veterinary use of the technologies.
About Braasch Biotech
Braasch Biotech has pioneered a novel field of therapeutic approaches utilizing Somatovac® technologies. Currently in the Product Pipeline are vaccines for livestock productivity enhancement, increased fertility, GH/IGF-1 deficiencies and obesity treatment. To date, Braasch has multiple regulatory submissions in progress on the use of vaccines in metabolic regulation. Braasch Biotech is a privately held biopharmaceutical with corporate offices in South Dakota.
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.
Contact Information
Jeralyn Kay Haffer
CEO and Chairman
Tel. 605-376-8752
Fax. 605-594-6256
jeralyn@braaschbiotech.com
Contact
Braasch Biotech LLC
Keith Haffer
605-376-8756
www.braaschbiotech.com
Keith Haffer
605-376-8756
www.braaschbiotech.com
Contact
Categories